REVOLUTION MEDICINES INC. - COMMON STOCK

44,42

08-января-25 16:45:00

15 мин. задержка

Акции

+0,09

+0,20%

Сегодняшний диапазон

44,26 - 45,25

ISIN

N/A

Источник

NASDAQ

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

06 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

05 дек 2024 16:05:49 Источник Nasdaq GlobeNewswire
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

03 дек 2024 22:38:42 Источник Nasdaq GlobeNewswire
Revolution Medicines Announces Commencement of Public Offering of Common Stock

02 дек 2024 16:31:20 Источник Nasdaq GlobeNewswire
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

02 дек 2024 07:30:02 Источник Nasdaq GlobeNewswire
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

27 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

06 ноя 2024 16:02:32 Источник Nasdaq GlobeNewswire
Revolution Medicines to Participate in Upcoming Investor Conferences

05 ноя 2024 09:00:30 Источник Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

30 окт 2024 16:05:23 Источник Nasdaq GlobeNewswire
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

25 окт 2024 04:15:00 Источник Nasdaq GlobeNewswire
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

23 окт 2024 06:00:49 Источник Nasdaq GlobeNewswire
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

21 окт 2024 16:05:39 Источник Nasdaq GlobeNewswire
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

07 окт 2024 09:00:01 Источник Nasdaq GlobeNewswire
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

07 авг 2024 16:05:41 Источник Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

31 июл 2024 16:05:11 Источник Nasdaq GlobeNewswire
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

11 июл 2024 12:00:53 Источник Nasdaq GlobeNewswire
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

08 июл 2024 16:05:00 Источник Nasdaq GlobeNewswire
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

05 июн 2024 16:05:28 Источник Nasdaq GlobeNewswire
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

08 май 2024 16:02:54 Источник Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

01 май 2024 16:05:56 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.